智通财经APP获悉，宜明昂科-B(01541)午前涨超3%，截至发稿，涨3.36%，报5.53港元，成交额716.89万港元。
消息面上，近日，宜明昂科-B公布2024年业绩，收入约7414.9万元，同比增长约191.1倍；研发开支同比增加10.6%至3.23亿元。公司拥有人应占亏损约3.16亿元，同比收窄16.76%；每股亏损0.84元。公告称，收入增长主要归因于根据公司与Axion Bio, Inc.达成的授权及合作协议收取首付款及近期付款。
研发开支增长主要归因于临床前及CMC开支增加4360万元(主要由于临床试验使用的IMM2510及IMM0306的生产及CDMO开支增加)；及薪金及相关福利费用因2024年临床团队不断扩大而增加740元，与公司持续推进及扩大药物管线的研发工作相符合；部分被临床试验开支及以股份为基础的付款减少1830万元(由于临床CRO开支及实验室开支减少400万元；及以股份为基础的付款减少1430万元(由于截至2024年12月31日止年度已归属的受限制股份数目减少)所抵销。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.